NAUT · 10-Q · 2026Q1 · Full report
Quarterly Results Snapshot
Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 41 · Surprise 22
Nautilus reported a net loss of $14.7 million for the three months ended March 31, 2026. The net loss improved by $1.9 million, or 12%, versus a $16.6 million loss in the same period of 2025. The company stated it has an accumulated deficit of $346.7 million as of March 31, 2026. Management reiterated that it expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances development and commercialization of the Nautilus Voyager platform.
Key facts
- Nautilus' net loss was $14.7 million for the three months ended March 31, 2026.
- Nautilus does not have any products available for commercial sale and has not generated any revenue since inception.
- Nautilus was founded in 2016.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | — | Nautilus' net loss was $14.7 million for the three months ended March 31, 2026. |